EnvoyAI Partner:


maxq ai
if_Laptop_B_104985.png
Website: www.maxq.ai
if_290_279051.png
Year Founded: 2013
if_search_244366.png
Area of Focus/Speciality: We are focused on building applications to address time-sensitive, life-threatening conditions, such as stroke and traumatic brain injury.
if__location_1964213.png
Company Headquarters: Tel Aviv, Israel and Andover, MA, USA
cortechs labs linkedin page
CorTechs_Labs twitter profile

MaxQ AI

About MaxQ AI

MaxQ AI is at the forefront of Medical Diagnostic AI. Our mission is to meaningfully reduce misdiagnosis and healthcare costs by making artificial intelligence (AI) intrinsic to the diagnostic process for time sensitive and life-threatening conditions. We are transforming healthcare by empowering physicians to provide ‘smarter care’ through intelligent imaging with AI actionable insights. Our team of deep learning and machine vision experts develop innovative software that uses AI to interpret medical images and surrounding patient data. Working with world-class clinical and industry partners, our software enables physicians to make faster, more accurate decisions when diagnosing stroke, brain trauma, and other serious conditions.

The complete Accipio platform will support the Radiologist, Emergency Room, and Neurorad teams with a fully-automated solution. Accipio uses MaxQ AI’s INSIGHT™ method, providing prioritization (Ix1), annotation (Ax2), and expert-level diagnostic rule out (Dx2). The complete ICH solution for head trauma and stroke care promises to:

  • Increase bleed detection and reduce missed bleeds through real-time triaged and prioritize notification of non-contrast head CT – because minutes matter;
  • Enhance escalation and intervention confidence, including mobilization of the Stroke, tPA and Operating Room teams for mechanical clot removal; the right care readied faster;
  • Assist stroke treatment: including tPA administration and mechanical intervention, that can help avoid errors leading to clinical, economic and potentially litigious issues.
if__location_1964213.png

Reference Sites:

  • Capital Health

End-User Testimonials

Radiologist

"We serve multiple hospitals where we may have several CT head cases with other stat exams to read – with no way of knowing what is the most acute without adding more radiologists – this risk exposure is amplified when a priority stroke case hits the ED. Having an intelligent agent prioritize these cases would increase safety, improve patient care and inform staffing decisions."

Mark C. DeLano, MD, FACR; Advanced Radiology Services, PC; Michigan State University

MaxQ AI Leadership
team-gene-saragnese1-1-1

Gene Saragnese

Chairman and CEO

team-michael-rosenberg1-1-1

Michael Rosenberg

Co-Founder & Chief Financial Officer

team-robert-mehler1-1-1-1

Robert Mehler

Co-Founder & Chief Operating Officer

team-chris-schnee1-3

Chris Schnee

SVP Commercial Operations

MaxQ AI Machine | The Accipio Platform

MaxQ AI is directly responsible for product and clinical representations

  • maxq ai machine
Our initial suite of applications – Accipio IxTM, Accipio AxTM, Accipio DxTM – are designed to enable doctors to make faster, more accurate decisions regarding brain bleeds. Accipio IxTM (FDA Cleared & CE Approved) identifies suspected brain bleeds in CT scans and prioritizes those cases for clinical assessment. Accipio AxTM will annotate suspected brain bleed(s) by adding Region of Interest markings for clinical review to suspect areas on CT scans. Accipio Dx will provide a diagnostic rule-out of suspected bleed on CT.

The Accipio platform will support the Radiologist, Emergency Room and Neuro-rad teams with a fully-automated solution. Accipio uses MaxQ Al's INSIGHT™ method, providing identification & prioritization (lx1), annotation (Ax2) and expert-level diagnostic rule out (Dx2). The complete ICH solution for head trauma and stroke care promises to:

  • Increase bleed detection and reduce missed bleeds through real-time triaged and prioritize notification of non-contrast head CT – because minutes matter;
  • Enhance escalation and intervention confidence, including mobilization of the Stroke, tPA and Operating Room teams for mechanical clot removal; the right care readied faster;
  • Assist stroke treatment: including tPA administration and mechanical intervention, that can help avoid errors leading to clinical, economic and potentially litigious issues.

 

US Regulatory Status: Accipio Ix is FDA Cleared, CE Approved. Accipio Ax and Dx are not FDA Cleared, not CE Approved and for investigational use only.